Fluticasone furoate for the treatment of childhood asthma

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Inhaled corticosteroids offer substantial benefit in controlling symptoms for the vast majority of children with asthma. However, poor adherence to therapy is very common, especially among older children and adolescents as they transition to self-management of their disease. The introduction of once-daily inhaled fluticasone furoate, either alone or in combination with the long-acting β-agonist, vilanterol, simplifies chronic asthma therapy and may improve adherence and as a result, outcomes in this vulnerable population. Opportunities exist for additional study of this agent in younger children, particularly with regard to safety and growth suppression. This review provides an overview of the pharmacology, safety and efficacy data regarding use of fluticasone furoate in the treatment of childhood asthma.

Original languageEnglish (US)
Pages (from-to)391-404
Number of pages14
JournalExpert Review of Respiratory Medicine
Volume9
Issue number4
DOIs
StatePublished - Aug 1 2015

Fingerprint

Asthma
Safety
Vulnerable Populations
Self Care
Adrenal Cortex Hormones
Therapeutics
Pharmacology
Growth
fluticasone furoate
vilanterol

Keywords

  • asthma
  • efficacy
  • fluticasone furoate
  • pediatric
  • pharmacodynamics
  • pharmacokinetics
  • safety

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Immunology and Allergy
  • Public Health, Environmental and Occupational Health

Cite this

Fluticasone furoate for the treatment of childhood asthma. / Phan, Hanna; Brown, Mark A.

In: Expert Review of Respiratory Medicine, Vol. 9, No. 4, 01.08.2015, p. 391-404.

Research output: Contribution to journalArticle

@article{803b62746a844189ac933bbba0cdfc47,
title = "Fluticasone furoate for the treatment of childhood asthma",
abstract = "Inhaled corticosteroids offer substantial benefit in controlling symptoms for the vast majority of children with asthma. However, poor adherence to therapy is very common, especially among older children and adolescents as they transition to self-management of their disease. The introduction of once-daily inhaled fluticasone furoate, either alone or in combination with the long-acting β-agonist, vilanterol, simplifies chronic asthma therapy and may improve adherence and as a result, outcomes in this vulnerable population. Opportunities exist for additional study of this agent in younger children, particularly with regard to safety and growth suppression. This review provides an overview of the pharmacology, safety and efficacy data regarding use of fluticasone furoate in the treatment of childhood asthma.",
keywords = "asthma, efficacy, fluticasone furoate, pediatric, pharmacodynamics, pharmacokinetics, safety",
author = "Hanna Phan and Brown, {Mark A}",
year = "2015",
month = "8",
day = "1",
doi = "10.1586/17476348.2015.1068692",
language = "English (US)",
volume = "9",
pages = "391--404",
journal = "Expert Review of Respiratory Medicine",
issn = "1747-6348",
publisher = "Expert Reviews Ltd.",
number = "4",

}

TY - JOUR

T1 - Fluticasone furoate for the treatment of childhood asthma

AU - Phan, Hanna

AU - Brown, Mark A

PY - 2015/8/1

Y1 - 2015/8/1

N2 - Inhaled corticosteroids offer substantial benefit in controlling symptoms for the vast majority of children with asthma. However, poor adherence to therapy is very common, especially among older children and adolescents as they transition to self-management of their disease. The introduction of once-daily inhaled fluticasone furoate, either alone or in combination with the long-acting β-agonist, vilanterol, simplifies chronic asthma therapy and may improve adherence and as a result, outcomes in this vulnerable population. Opportunities exist for additional study of this agent in younger children, particularly with regard to safety and growth suppression. This review provides an overview of the pharmacology, safety and efficacy data regarding use of fluticasone furoate in the treatment of childhood asthma.

AB - Inhaled corticosteroids offer substantial benefit in controlling symptoms for the vast majority of children with asthma. However, poor adherence to therapy is very common, especially among older children and adolescents as they transition to self-management of their disease. The introduction of once-daily inhaled fluticasone furoate, either alone or in combination with the long-acting β-agonist, vilanterol, simplifies chronic asthma therapy and may improve adherence and as a result, outcomes in this vulnerable population. Opportunities exist for additional study of this agent in younger children, particularly with regard to safety and growth suppression. This review provides an overview of the pharmacology, safety and efficacy data regarding use of fluticasone furoate in the treatment of childhood asthma.

KW - asthma

KW - efficacy

KW - fluticasone furoate

KW - pediatric

KW - pharmacodynamics

KW - pharmacokinetics

KW - safety

UR - http://www.scopus.com/inward/record.url?scp=84937944926&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937944926&partnerID=8YFLogxK

U2 - 10.1586/17476348.2015.1068692

DO - 10.1586/17476348.2015.1068692

M3 - Article

VL - 9

SP - 391

EP - 404

JO - Expert Review of Respiratory Medicine

JF - Expert Review of Respiratory Medicine

SN - 1747-6348

IS - 4

ER -